Loading company
Biodesix Inc.
BDSX · Nasdaq · ·
Next earnings: November 2, 2026
$29.00-4.9%Sep 29 close
- 1M
- +8.1%
- 6M
- +110.3%
- 1Y
- +284.0%
- 5Y
- -82.4%
BDSX · Nasdaq · ·
Next earnings: November 2, 2026
$29.00-4.9%Sep 29 close
Biodesix Inc. is scheduled to report next on November 2, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $26.9M | $20M | +34.18% |
| Profit | -$7.3M | -$11.5M | +36.58% |
| Profit per share | -$0.71 | -$1.56 | +54.49% |
| Free Cash Flow | -$1.8M | -$6.6M | +73.42% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Biodesix delivered another strong quarter, highlighted by 34% revenue growth, 42% growth in Diagnostic Testing revenue, and gross margins, which increased to 82%,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests , including the Nodify Lung® Nodule Risk Assessment test and the IQLung® Cancer Treatment Guidance test, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Biodesix Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Biodesix Inc. has no earnings call transcript available.